---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346859"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-08-12T20:10:20+00:00"
generated_at: "2026-08-12T20:12:46.763811+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q2 2026 net loss $18.0M; cash $90.0M funds into Q4 2027

## Summary
- Net loss $18.0M vs $21.0M in Q2 2025; R&D expense $13.8M vs $16.2M prior year.
- Cash, equivalents and investments $90.0M as of Jun 30, 2026, expected to fund ops into Q4 2027.
- ACR-368 Phase 2b prespecified interim analysis in serous EC on track for H2 2026; Phase 3 initiation planned H1 2027.
- ACR-2316 entered randomized dose expansion at 120mg and 160mg oral QD in AP3-prioritized tumor types.
- IND filing for CDK11 inhibitor candidate planned H1 2027; additional AP3 programs to start in 2026.

## SEC filing metadata
- accession: 0001193125-26-346859
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-08-12T20:10:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/0001193125-26-346859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346859
- JSON: https://secwatch.observer/filing/0001193125-26-346859.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.